AURA BIOSCIENCES INC.

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

17 10 2024 15:05:00 提供 Nasdaq GlobeNewswire

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

12 9 2024 05:30:00 提供 Nasdaq GlobeNewswire

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024

03 9 2024 15:05:00 提供 Nasdaq GlobeNewswire

Aura Biosciences to Participate in Upcoming Investor Conferences

28 8 2024 15:05:00 提供 Nasdaq GlobeNewswire

Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting

26 8 2024 15:05:00 提供 Nasdaq GlobeNewswire

Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights

08 8 2024 06:00:01 提供 Nasdaq GlobeNewswire

Aura Biosciences to Participate in the Jefferies Global Healthcare Conference

30 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024

23 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

09 5 2024 06:00:01 提供 Nasdaq GlobeNewswire

Aura Biosciences to Participate in Upcoming Investor Conferences

08 5 2024 06:00:00 提供 Nasdaq GlobeNewswire